Article in Radiology. Cardiothoracic imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 2 institutions in 1 country.
Be'eri Niego *From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).ORCID 0000-0001-6714-9131
Bianca Jupp *From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).
Nicholas A ZiaFrom the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).
Rong XuFrom the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).ORCID 0000-0002-5510-3678
Edwina JapFrom the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).ORCID 0000-0001-5437-6247
Martin EzeaniFrom the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).ORCID 0000-0002-1270-9469
Asif NoorFrom the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).ORCID 0000-0001-5713-6070
Paul S DonnellyFrom the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).ORCID 0000-0001-5373-0080
Christoph E Hagemeyer *From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).ORCID 0000-0002-7114-4023
Karen Alt *From the NanoBiotechnology Laboratory (B.N., R.X., M.E., C.E.H.) and NanoTheranostics Laboratory (E.J., K.A.), Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia (B.J.); and School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Australia (N.A.Z., A.N., P.S.D.).ORCID 0000-0002-6252-1931
Monash University · AUThe University of Melbourne · AU
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Purpose To develop an approach for in vivo detection of interstitial cardiac fibrosis using PET with a peptide tracer targeting proteolyzed collagen IV (T-peptide). Materials and Methods T-peptide was conjugated to the copper chelator MeCOSar (chemical name, 5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid) and radiolabeled with copper 64 (
Indexed as
CopperPositron Emission Tomography Computed TomographyAnimalsCollagen Type IVFibrosisMaleMiceMice, TransgenicMolecular ImagingMolecular ProbesPeptidesPositron-Emission TomographyCollagen Type IVCopperMolecular ProbesPeptidesDiffuse Cardiac FibrosisMolecular ImagingMolecular Peptide ProbePET/CT
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Molecular Imaging of Diffuse Cardiac Fibrosis with a Radiotracer That Targets Proteolyzed Collagen IV. · full record | OpenQuestion